# Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma

> **NCT03801668** · PHASE3 · UNKNOWN · sponsor: **Huazhong University of Science and Technology** · enrollment: 294 (estimated)

## Conditions studied

- Gastric Cancer

## Interventions

- **DRUG:** Albumin-bound Paclitaxel plus S-1
- **DRUG:** Oxaliplatin plus S-1

## Key facts

- **NCT ID:** NCT03801668
- **Lead sponsor:** Huazhong University of Science and Technology
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2019-03-08
- **Primary completion:** 2022-12-31
- **Final completion:** 2023-03-31
- **Target enrollment:** 294 (ESTIMATED)
- **Last updated:** 2022-01-04

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03801668

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03801668, "Albumin-bound Paclitaxel Plus S-1 Versus SOX as First-line Treatment in Advanced or Recurrent Gastric Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03801668. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*